Recommendation for use of 15- and 20-valent pneumococcal conjugate vaccines in Korean infants and children
Authors:
- Ki Wook YunKYKi Wook Yun
- Dong Hyun KimDKDong Hyun Kim
- Jong Gyun AhnJAJong Gyun Ahn
- Byung-Wook EunBEByung-Wook Eun
- Jina LeeJLJina Lee
- Taek-Jin LeeTLTaek-Jin Lee
- Hyunju LeeHLHyunju Lee
- Dae Sun JoDJDae Sun Jo
- Eun Young ChoECEun Young Cho
- Hye-Kyung ChoHCHye-Kyung Cho
- Soo-Han ChoiSCSoo-Han Choi
- Young June ChoeYCYoung June Choe
Open Access
- 15 January 2026
- journal article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (1) , 76-83
Abstract
Pneumococcal disease remains the leading cause of morbidity in young children worldwide. Recent advances have expanded pneumococcal conjugate vaccines (PCVs) beyond 13-valent (PCV13) to 15-valent (PCV15) and 20- valent (PCV20) vaccines, which add 2 and 7 serotypes, respectively, thereby broadening their potential protective effects against invasive pneumococcal disease (IPD). Although policies vary among countries, Korea incorporated PCV15 and PCV20 into its National Immunization Program for children in April 2024 and October 2025, respectively, an implementation that is considered within the context of global epidemiology and policy trends. This review discusses evidence of the immunogenicity and safety of PCV15 and PCV20 from clinical trials and early postlicensure data, examines the serotype distribution and IPD burden in Korea alongside data from other regions, and summarizes vaccination recommendations for healthy and high-risk pediatric populations, including considerations for catch-up, interchangeability, and their coadministration. By integrating national updates and global evidence, this review aims to support clinicians and policymakers worldwide optimizing pneumococcal vaccination strategies for children.Keywords
This publication has 24 references indexed in Scilit:
- A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccineVaccine, 2025
- A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of AgeThe Pediatric Infectious Disease Journal, 2024
- A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Clinical Infectious Diseases, 2023
- A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Vaccine, 2023
- A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Vaccine, 2022
- A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Vaccine, 2022
- Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014–2019Vaccine, 2021
- Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from invasive infections after optional use of the 7-valent conjugate vaccine in Korea, 2006–2010Diagnostic Microbiology and Infectious Disease, 2014
- Genetic structure of Streptococcus pneumoniae isolated from children in a tertiary care university hospital, in Korea, 1995 to 2005Diagnostic Microbiology and Infectious Disease, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009